EXTON, Pa. and CLEVELAND--(BUSINESS WIRE)--Absorption Systems LP, the authority on drug absorption, and ChanTest, the leading experts in ion channels, GPCRs (G-protein coupled receptors) and in vitro cardiac risk assessment, today announced they will collaborate to expand Absorption Systems’ suite of drug metabolism studies to provide data on the impact that a therapy may have on the heart. Absorption Systems’ pharmaceutical and biotechnology industry customers that work with the company to secure in vitro drug metabolism data for FDA submissions can now request studies that use ChanTest’s extensive library of cell lines for assessing a drug’s impact on cardiac tissue. The ChanTest assays will be available through the Absorption Systems Safety Suite™.
